245 related articles for article (PubMed ID: 22946890)
1. Oral bioavailability of dabigatran etexilate (Pradaxa(®) ) after co-medication with verapamil in healthy subjects.
Härtter S; Sennewald R; Nehmiz G; Reilly P
Br J Clin Pharmacol; 2013 Apr; 75(4):1053-62. PubMed ID: 22946890
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics and pharmacodynamics of the direct oral thrombin inhibitor dabigatran in healthy elderly subjects.
Stangier J; Stähle H; Rathgen K; Fuhr R
Clin Pharmacokinet; 2008; 47(1):47-59. PubMed ID: 18076218
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetic and pharmacodynamic effects of comedication of clopidogrel and dabigatran etexilate in healthy male volunteers.
Härtter S; Sennewald R; Schepers C; Baumann S; Fritsch H; Friedman J
Eur J Clin Pharmacol; 2013 Mar; 69(3):327-39. PubMed ID: 22782539
[TBL] [Abstract][Full Text] [Related]
4. Switching from enoxaparin to dabigatran etexilate: pharmacokinetics, pharmacodynamics, and safety profile.
Clemens A; van Ryn J; Sennewald R; Yamamura N; Stangier J; Feuring M; Härtter S
Eur J Clin Pharmacol; 2012 May; 68(5):607-16. PubMed ID: 22252796
[TBL] [Abstract][Full Text] [Related]
5. Decrease in the oral bioavailability of dabigatran etexilate after co-medication with rifampicin.
Härtter S; Koenen-Bergmann M; Sharma A; Nehmiz G; Lemke U; Timmer W; Reilly PA
Br J Clin Pharmacol; 2012 Sep; 74(3):490-500. PubMed ID: 22348256
[TBL] [Abstract][Full Text] [Related]
6. The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects.
Stangier J; Rathgen K; Stähle H; Gansser D; Roth W
Br J Clin Pharmacol; 2007 Sep; 64(3):292-303. PubMed ID: 17506785
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics and pharmacodynamics of dabigatran etexilate, an oral direct thrombin inhibitor, with coadministration of digoxin.
Stangier J; Stähle H; Rathgen K; Roth W; Reseski K; Körnicke T
J Clin Pharmacol; 2012 Feb; 52(2):243-50. PubMed ID: 21868715
[TBL] [Abstract][Full Text] [Related]
8. Influence of renal impairment on the pharmacokinetics and pharmacodynamics of oral dabigatran etexilate: an open-label, parallel-group, single-centre study.
Stangier J; Rathgen K; Stähle H; Mazur D
Clin Pharmacokinet; 2010 Apr; 49(4):259-68. PubMed ID: 20214409
[TBL] [Abstract][Full Text] [Related]
9. A semi-mechanistic absorption model to evaluate drug-drug interaction with dabigatran: application with clarithromycin.
Delavenne X; Ollier E; Basset T; Bertoletti L; Accassat S; Garcin A; Laporte S; Zufferey P; Mismetti P
Br J Clin Pharmacol; 2013 Jul; 76(1):107-13. PubMed ID: 23210726
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetic profile of the oral direct thrombin inhibitor dabigatran etexilate in healthy volunteers and patients undergoing total hip replacement.
Stangier J; Eriksson BI; Dahl OE; Ahnfelt L; Nehmiz G; Stähle H; Rathgen K; Svärd R
J Clin Pharmacol; 2005 May; 45(5):555-63. PubMed ID: 15831779
[TBL] [Abstract][Full Text] [Related]
11. Pharmacology, pharmacokinetics, and pharmacodynamics of dabigatran etexilate, an oral direct thrombin inhibitor.
Stangier J; Clemens A
Clin Appl Thromb Hemost; 2009; 15 Suppl 1():9S-16S. PubMed ID: 19696042
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetic interaction between oral lovastatin and verapamil in healthy subjects: role of P-glycoprotein inhibition by lovastatin.
Choi DH; Chung JH; Choi JS
Eur J Clin Pharmacol; 2010 Mar; 66(3):285-90. PubMed ID: 20012601
[TBL] [Abstract][Full Text] [Related]
13. New options with dabigatran etexilate in anticoagulant therapy.
Maegdefessel L; Spin JM; Azuma J; Tsao PS
Vasc Health Risk Manag; 2010 May; 6():339-49. PubMed ID: 20531953
[TBL] [Abstract][Full Text] [Related]
14. Coadministration of dabigatran etexilate and atorvastatin: assessment of potential impact on pharmacokinetics and pharmacodynamics.
Stangier J; Rathgen K; Stähle H; Reseski K; Körnicke T; Roth W
Am J Cardiovasc Drugs; 2009; 9(1):59-68. PubMed ID: 19178132
[TBL] [Abstract][Full Text] [Related]
15. Dose escalating safety study of a new oral direct thrombin inhibitor, dabigatran etexilate, in patients undergoing total hip replacement: BISTRO I.
Eriksson BI; Dahl OE; Ahnfelt L; Kälebo P; Stangier J; Nehmiz G; Hermansson K; Kohlbrenner V
J Thromb Haemost; 2004 Sep; 2(9):1573-80. PubMed ID: 15333033
[TBL] [Abstract][Full Text] [Related]
16. Investigation of the Effect of Lasmiditan on the Pharmacokinetics of P-Glycoprotein and Breast Cancer Resistance Protein Substrates.
Luffer-Atlas D; Wilbraham D; Posada MM; Landry J; Tsai M; Pearlman EM
J Clin Pharmacol; 2024 Jan; 64(1):94-102. PubMed ID: 37566903
[TBL] [Abstract][Full Text] [Related]
17. Effect of Daridorexant on the Pharmacokinetics of P-Glycoprotein Substrate Dabigatran Etexilate and Breast Cancer Resistance Protein Substrate Rosuvastatin in Healthy Subjects.
Anliker-Ort M; Dingemanse J; Janů L; Kaufmann P
Clin Drug Investig; 2023 Nov; 43(11):827-837. PubMed ID: 37858005
[TBL] [Abstract][Full Text] [Related]
18. Dabigatran does not prolong the QT interval with supratherapeutic exposure: a thorough QT study in healthy subjects.
Ring A; Rathgen K; Stangier J; Reilly P; Clemens A; Friedman J
Clin Drug Investig; 2013 May; 33(5):333-42. PubMed ID: 23519576
[TBL] [Abstract][Full Text] [Related]
19. The Effect of Verapamil, a P-gp Inhibitor, on the Pharmacokinetics, Safety, and Tolerability of Omadacycline in Healthy Adults: A Phase I, Open-Label, Single-Sequence Study.
Hunt TL; Tzanis E; Bai S; Manley A; Chitra S; McGovern PC
Eur J Drug Metab Pharmacokinet; 2021 Jan; 46(1):85-92. PubMed ID: 33180250
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics and pharmacodynamics of dabigatran etexilate, an oral direct thrombin inhibitor, are not affected by moderate hepatic impairment.
Stangier J; Stähle H; Rathgen K; Roth W; Shakeri-Nejad K
J Clin Pharmacol; 2008 Dec; 48(12):1411-9. PubMed ID: 18827075
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
